Table 1.

Population characteristics

CharacteristicsTotal patients, N = 670
Gender
 Women336 (50.1%)
 Men334 (49.9%)
Age (median, range)62.0 years (5–92)
Turn over timea (median, 95% CI; range)15 days (15–16; 7–35)
Tumor origin
 Gastrointestinal213 (31.8%)
 Brain152 (22.7%)
 Lung139 (20.7%)
 Breast55 (8.2%)
 Head and neck25 (3.7%)
 Genitourinary19 (2.8%)
 Carcinoma of unknown primary13 (1.94%)
 Skin/melanoma10 (1.5%)
 Gynecologic7 (1.0%)
 Erdheim-Chester disease6 (0.9%)
 Mesothelioma5 (0.74%)
 Otherb26 (3.88%)
Number of patients with ≥1 alteration (includes characterized alterations and VUSs)423 (63.1%)
Median number of alterations (range) (includes characterized alterations and VUSs)1 (0–26)
Number of patients with ≥1 characterized alteration322 (48.1%)
Median number of characterized alterations (range) in patients with alterations1 (0–13)
  • aTime from blood collection to results.

  • bOther included: lymphoma, n = 4; neuroendocrine carcinoma, n = 4; sarcoma, n = 3; Castleman disease, n = 2; thymoma, n = 2; chordoma, n = 1; desmoid tumor, n = 1; nerve sheath tumor, n = 1; myoepithelial carcinoma, n = 1; thymic carcinoma, n = 1, prolactinoma, n = 1; and unknown diagnosis, n = 5.

  • The majority of lung cancers were adenocarcinomas, with n = 118/139 = 84.9%. (The 21 remaining cases were squamous cell carcinoma, n = 12; small cell carcinoma, n = 7; adenosquamous, n = 1; carcinoid tumor, n = 1.)

  • Characterized alterations were defined at the gene variant level.